

Electronic Acknowledgement Receipt

EFS ID:	5883876
Application Number:	10786907
International Application Number:	
Confirmation Number:	6743
Title of Invention:	Modified antibody
First Named Inventor/Applicant Name:	Bjarne Bogen
Customer Number:	27572
Filer:	Fernando Alberdi/Andrea Blendea
Filer Authorized By:	Fernando Alberdi
Attorney Docket Number:	367315-000001/US
Receipt Date:	13-AUG-2009
Filing Date:	25-FEB-2004
Time Stamp:	15:12:49
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$470
RAM confirmation Number	1299
Deposit Account	080750
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment Submitted/Entered with Filing of CPA/RCE	Amendment_After_Final_and_RCE.PDF	1424367 8b0f3dcedfbca00abcf35e124c00c1ce0660a	no	20
Warnings:					
Information:					
2	Extension of Time	Petition_For_Ext_of_Time.PDF	118476 03e1320c93b38595d11c25e022f901862af3a0d8	no	1
Warnings:					
Information:					
3	Request for Continued Examination (RCE)	RCE.PDF	154182 66a0f5c2ab75edabacc7e41a1bfcbec180f13a	no	1
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
4	Transmittal Letter	IDS.PDF	479682 8e1c7b4e93e44a255d123db3e6d48e62775a0ab	no	5
Warnings:					
Information:					
5	NPL Documents	Biragyn_et_al_Genetic_Fusion_of_Chemokines_1999.PDF	863536 18604912d3b715c08f5296a6b95a170a14e0510	no	6
Warnings:					
Information:					
6	NPL Documents	Pluckthun_et_al_New_Protein_Engineering.PDF	1835777 78ecce58c5edc53ba13516e4d77c3c40f8a070	no	23
Warnings:					
Information:					
7	NPL Documents	Chen_et_al_Linkage_of_CD40L_2002.PDF	888574 00c66abcc903778911be8b4b1074b49cd94b4f93a	no	8
Warnings:					
Information:					

8	NPL Documents	Huang_et_al_Improved_Immuno-genicity_2004.PDF	883103 101b0b1894d7e1962f483c5f19ec0545d35d70a	no	8
Warnings:					
Information:					
9	NPL Documents	Huang_et_al_Enhanced_Anti-tumor_Immunity_2000.PDF	940507 90196c541ee8ea079c33841ee255dd1dc1164b	no	8
Warnings:					
Information:					
10	NPL Documents	Kriangkum_et_al_Bispecific_and_Bifunctional_2001.PDF	1260111 098c97383a814c4e44982c1b0e26e9c31cef32	no	10
Warnings:					
Information:					
11	NPL Documents	Van_Spriel_et_al_Immunotherapeutic_Perspective_2000.PDF	965536 70bbaae9776da11cd14152d047bee0159db	no	6
Warnings:					
Information:					
12	NPL Documents	Hoogenboom_Mix_and_Match_1997.PDF	335777 41de947570805327f364ee55a5a2d42d8cf8a	no	2
Warnings:					
Information:					
13	NPL Documents	HU_et_al_Minibody_1996.PDF	975758 214ca351d78413d896915ca368b4e4195c79398bb	no	7
Warnings:					
Information:					
14	NPL Documents	Biragyn_et_al_Toll_Like_Receptor_2002.PDF	680137 61702b78608d02ce541990ab1d4c1344ce925	no	5
Warnings:					
Information:					
15	NPL Documents	Lunde_et_al_TrojanBodies_and_Pepbodies_2002.PDF	582003 f36a338f8c6d9a32704cbe8108612ce505b6c0	no	7
Warnings:					
Information:					
16	NPL Documents	Lunde_et_al_Trojan_Bodies_Recombinant_Antibodies_2001.PDF	1390696 c76c3226c5980403c3cd956ff7cd4475a7db	no	14
Warnings:					
Information:					

17	1.501 Submission by Patent Owner	Ruffini_et_al_Idiotypic_Vaccination_2002.PDF	1652311 47b96a0a31bc0f1b2c22a548b05ee00fcd99	no	13
Warnings:					
Information:					
18	Information Disclosure Statement (IDS) Filed (SB/08)	Form_1449.PDF	69956 c0ff75d6f00c14e5532401d51ff5e991d0162	no	1
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
19	Fee Worksheet (PTO-875)	fee-info.pdf	31848 89b8f58ca86c1ff33aa05f3686a51ff6c1f886c9a49	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			15532347		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					